Under construction – not a live service
Sign in
Taking people in RussiaNo phase

Using a blood marker to judge heart risks after bypass surgery in heart failure

Follows people with heart failure after bypass surgery, using a GDF-15 blood test.

Key facts

Who runs it
Tomsk National Research Medical Center of the Russian Academy of Sciences
Where
Tomsk, RussiaSee the site
Trial code
Registry title
Risk Stratification of MACE in Heart Failure Patients Who Undergoing CABG
Status
Recruiting
People taking part
160 people, planned
Started
4 Mar 2026
Expected to end
Mar 2028
Type of study
Observational
Record updated
6 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with heart failure who are planning to have coronary artery bypass grafting (CABG) surgery.

Sex
All sexes can join.
Disease stage
Heart failure, with coronary artery bypass grafting planned.

Main reasons for not taking part

  • Myocardial infarction
  • Stroke
  • Implanted devices
  • Need for other heart surgery besides bypass grafting (valve repair, aneurysm)
  • Severe kidney problems (GFR <30 ml/min/1.73 m2)

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Heart Failure
  • Planned coronary artery bypass grafting

Who cannot take part

  • Myocardial infarction
  • Stroke
  • Need for additional cardiac surgery other than coronary artery bypass grafting (valve repair, aneurysm)
  • Severe comorbidities: active cancer; infiltrative cardiac diseases (sarcoidosis, amyloidosis, storage diseases); autoimmune diseases; acute infectious diseases and exacerbations of chronic somatic diseases
  • Severe renal dysfunction (GFR <30 ml/min/1.73 m2)
  • Presence of implanted devices

Where in Russia

  • Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesTomsk, RussiaContact: Елена Кужелева, PhDTaking people

About the trial

What the trial wants to find out

PROFILE-HF is a multicenter, observational, prospective study of the clinical course and outcomes of chronic heart failure (HF) and coronary artery disease (CAD) in patients undergoing coronary artery bypass grafting (CABG).

Read full original descriptionShow less

The objective of the study is to develop a method for assessing the risk of adverse cardiovascular events in patients with CAD and HF who have undergone CABG, based on preoperative GDF-15 concentrations.

The study will have a 12-month follow-up period; one in-person visit is planned at the end of the follow-up period. If it is not possible to visit a doctor in person, information will be collected through telephone contact with the patient or his relative or person caring for the patient.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Risk Stratification of MACE Based on GDF-15 in Heart Failure Patients Who Undergoing Coronary Artery Bypass Grafting: an Observational Multicenter Prospective Study
Plain-language title
Using a blood marker to judge heart risks after bypass surgery in heart failureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
6 October 2026